دورية أكاديمية
أعرض في EDS

Circulating CD8 + T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patients.

التفاصيل البيبلوغرافية
العنوان: Circulating CD8 + T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patients.
المؤلفون: Lin KR; Clinical Research Institute, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), NO. 81 North of Lingnan Avenue, Foshan, 528000, Guangdong, China., Pang DM; Department of Breast Oncology, Cancer Center, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, 528000, Guangdong, China., Jin YB; Clinical Research Institute, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), NO. 81 North of Lingnan Avenue, Foshan, 528000, Guangdong, China., Hu Q; Department of Breast Oncology, Cancer Center, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, 528000, Guangdong, China., Pan YM; Clinical Research Institute, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), NO. 81 North of Lingnan Avenue, Foshan, 528000, Guangdong, China., Cui JH; Clinical Research Institute, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), NO. 81 North of Lingnan Avenue, Foshan, 528000, Guangdong, China., Chen XP; Clinical Research Institute, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), NO. 81 North of Lingnan Avenue, Foshan, 528000, Guangdong, China., Lin YX; Department of Breast Oncology, Cancer Center, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, 528000, Guangdong, China., Mao XF; Clinical Research Institute, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), NO. 81 North of Lingnan Avenue, Foshan, 528000, Guangdong, China., Duan HB; Department of Breast Oncology, Cancer Center, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, 528000, Guangdong, China., Luo W; Clinical Research Institute, First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), NO. 81 North of Lingnan Avenue, Foshan, 528000, Guangdong, China. luowei@fsyyy.com.
المصدر: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2018 Nov; Vol. 67 (11), pp. 1743-1752. Date of Electronic Publication: 2018 Aug 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York, NY : Springer International, c1982-
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*immunology , CD8-Positive T-Lymphocytes/*immunology , Complementarity Determining Regions/*metabolism , Receptor, ErbB-2/*metabolism , Receptors, Antigen, T-Cell, alpha-beta/*metabolism, Adult ; Aged ; Amino Acid Sequence ; Biomarkers, Tumor/analysis ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Prognosis ; Sequence Homology
مستخلص: Purpose: CD8 + T cells are primarily cytotoxic cells that provide immunological protection against malignant cells. Considerable evidence suggests that the T-cell repertoire is closely associated with the host immune response and the development of cancer. In this study, we explored the characteristics of the circulating CD8 + T-cell repertoire and their potential value in predicting the clinical response of breast cancer patients to chemotherapy.
Experimental Design: We applied a high-throughput TCR β-chain sequencing method to characterize the CD8 + T-cell repertoire of the peripheral blood from 26 breast cancer patients. In addition, changes in the circulating CD8 + T-cell repertoire during chemotherapy were analyzed.
Results: We found that the HEC ratios of the CD8 + T-cell repertoires from HER2 + breast cancer patients were significantly higher than those of HER2 - patients, suggesting that the HER2 protein is released into circulation where it is targeted by CD8 + T cells. Several Vβ and CDR3 motifs preferentially used in HER2 + patients were identified. Besides, we found that the circulating CD8 + T-cell repertoires evolved during chemotherapy and correlated with patient clinical responses to chemotherapy. Increased CD8 + T-cell repertoire heterogeneity during chemotherapy was associated with a better clinical response.
Conclusions: Although functional studies of clonally expanded CD8 + T-cell populations are clearly required, our results suggest that the circulating CD8 + T-cell repertoire reflects the characteristics of the tumor-associated biomolecules released into the blood and correlates with the clinical responses of the patients to chemotherapy which might assist in making treatment decisions.
References: Bioinformatics. 2006 Jul 1;22(13):1658-9. (PMID: 16731699)
Cell Mol Immunol. 2009 Apr;6(2):105-10. (PMID: 19403059)
Sci Rep. 2015 Sep 02;5:13664. (PMID: 26329277)
Nature. 2017 Jul 6;547(7661):94-98. (PMID: 28636589)
Genome Res. 2009 Oct;19(10):1817-24. (PMID: 19541912)
Clin Exp Immunol. 2008 Dec;154(3):316-24. (PMID: 18811695)
Mol Cell Biol. 2014 Jul;34(14):2566-80. (PMID: 24797073)
Breast Care (Basel). 2015 Jul;10(3):211-9. (PMID: 26557827)
Breast Cancer Res. 2011;13(6):R117. (PMID: 22112244)
Cancer Treat Rev. 2016 May;46:9-19. (PMID: 27055087)
Cell Res. 2017 Apr;27(4):461-482. (PMID: 28290464)
Nat Commun. 2016 Apr 04;7:11153. (PMID: 27040081)
Int J Oncol. 2016 Aug;49(2):471-8. (PMID: 27278091)
J Pathol. 2013 Dec;231(4):433-440. (PMID: 24027095)
J Pathol. 2016 Aug;239(4):450-8. (PMID: 27171315)
Clin Cancer Res. 2007 May 1;13(9):2714-21. (PMID: 17473204)
Oncoimmunology. 2016 Aug 5;5(10):e1219010. (PMID: 27853640)
Am J Cancer Res. 2014 Nov 19;4(6):924-33. (PMID: 25520880)
Cell. 2017 Nov 2;171(4):934-949.e16. (PMID: 29033130)
Cancer Immunol Res. 2016 Oct;4(10):835-844. (PMID: 27587469)
Sci Rep. 2018 Feb 1;8(1):2171. (PMID: 29391594)
Mol Biotechnol. 2008 Sep;40(1):101-11. (PMID: 18463990)
Clin Chem. 2000 Feb;46(2):175-82. (PMID: 10657373)
Sci Transl Med. 2014 May 28;6(238):238ra70. (PMID: 24871131)
Gut. 2018 Apr;67(4):644-653. (PMID: 28188172)
J Am Coll Surg. 2015 Jun;220(6):1063-9. (PMID: 25868410)
Ann Surg. 2015 Sep;262(3):434-9; discussion 438-9. (PMID: 26222764)
Genome Med. 2015 Nov 19;7(1):117. (PMID: 26582264)
Oncology (Williston Park). 2015 Oct;29(10):733-8. (PMID: 26470896)
Oncoimmunology. 2015 Apr 2;4(8):e1021537. (PMID: 26405574)
Nat Rev Clin Oncol. 2011 Mar;8(3):151-60. (PMID: 21364688)
Breast Cancer Res. 2015 Mar 10;17:34. (PMID: 25849846)
معلومات مُعتمدة: 81402255 National Natural Science Foundation of China; 2016A030306050 Guangdong Province Natural Science Funds for Distinguished Young Scholar; 2014A030313803 Guangdong Province Natural Science Funds; 2015AG10002 Science and Technology Innovation Platform in Foshan City; 2015TQ01R462 "Guangdong Te Zhi Program" youth science and technology talent project
فهرسة مساهمة: Keywords: Breast cancer; CD8+ T-cell repertoire; Clinical response; HER2 expression status
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Complementarity Determining Regions)
0 (Receptors, Antigen, T-Cell, alpha-beta)
EC 2.7.10.1 (ERBB2 protein, human)
EC 2.7.10.1 (Receptor, ErbB-2)
تواريخ الأحداث: Date Created: 20180901 Date Completed: 20181029 Latest Revision: 20240426
رمز التحديث: 20240426
مُعرف محوري في PubMed: PMC11028329
DOI: 10.1007/s00262-018-2213-1
PMID: 30167861
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0851
DOI:10.1007/s00262-018-2213-1